Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

iate and complete pre-clinical studies and clinical trials for its product candidates; the possibility that results of pre- clinical studies are not necessarily predictive of clinical trial results; and those other risks factors that are described more fully in the Company's filings with the Securities and Exchange Commission. Targanta does not undertake any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

Contacts:

George Eldridge (investors) Tony Russo (media)

Senior Vice President Chairman & CEO

Finance & Administration Russo Partners LLC

and Chief Financial Officer (212) 845-4251

Targanta Therapeutics Corporation

(617) 577-9020 x212


'/>"/>
SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) ... genome engineering, today announced the appointment of Dr. ... Dr. Scharenberg is an attending physician ... of Pediatrics and Immunology at the University of ...
... Pharma, Inc. is pleased to announce that it has ... its lead drug for the treatment of stroke and ... A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single ... of Oral and Intravenous Administration of Methamphetamine Hydrochloride in ...
... For most people, the clock changes just twice a year ... Disorder (N24HWD, or Non-24), their internal body clock changes ... it is estimated that approximately 65,000 – 95,000 people suffer ... period can advance by about 15 minutes each night. Patients ...
Cached Biology Technology:Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics 2Sinapis Pharma Completes Phase I Trial 2New Website Targets Common Sleep Disorder in Blind Individuals 2
(Date:4/22/2014)... April 22, 2014 Scientists from the Florida campus ... protein complex that plays a critical but previously unknown ... study, which showed a novel role for a protein ... the journal eLife , a publisher supported by ... and the Wellcome Trust. , "This is a critical ...
(Date:4/22/2014)... PETA International Science Consortium Ltd.,s nanotechnology expert will present ... nanomaterial hazard assessment" at the 7th International Nanotoxicology ... Antalya, Turkey. , Dr. Monita Sharma will outline ... US National Academy of Sciences, " Toxicity Testing in ... which recommends use of non-animal methods involving human cells ...
(Date:4/22/2014)... American Societies for Experimental Biology (FASEB) has released ... how funding from the National Institutes of Health (NIH) ... Rico. "FASEB is pleased to make these factsheets available ... NIH to their state," said FASEB President, Margaret K. ... for biomedical research funding, investing $29.2 billion in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
... McGill University,s upcoming Conference on Global Food Security (Sept. ... in key organizations around the world to discuss solutions ... radar screens, but which has not gone away. ... own hemisphere, where Haiti has been hammered by hurricanes ...
... and economics will join forces at the University of ... also host an exhibition of some of the region,s ... and the environment. Today,s event will also see ... and the Environment (I-SEE) by David Willetts MP, Shadow ...
... immune-defense cells influenced by embryonic stem cell-derived cells can ... all without the use of immunosuppressive drugs. The ... (VA) Medical Center finding has implications for possible improvements ... study results appeared Friday in the online journal ...
Cached Biology News:McGill conference on Global Food Crisis draws impressive list of international participants 2McGill conference on Global Food Crisis draws impressive list of international participants 3University to showcase cutting edge environmental research 2Embryonic stem cells might help reduce transplantation rejection 2
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Fixed Angle Polypropylene Rotor designed for ... Centra CL3/CL3R** and Centra-MP4/MP4R*. A translucent ... /MP4, ,EXCLUSIVE polypropylene rotor design provides ... repeatedly autoclaved. Polypropylene rotors are ...
Biology Products: